Below are the most recent publications written about "Alkylating Agents" by people in Profiles.
-
Kodati S, Weng CY. Current and Emerging Pharmaceutical Therapies for Noninfectious Uveitis. Int Ophthalmol Clin. 2019; 59(1):111-126.
-
Valdez BC, Tang X, Li Y, Murray D, Liu Y, Popat U, Champlin RE, Andersson BS. Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells. Exp Hematol. 2018 11; 67:49-59.e1.
-
Puduvalli VK, Chaudhary R, McClugage SG, Markert J. Beyond Alkylating Agents for Gliomas: Quo Vadimus? Am Soc Clin Oncol Educ Book. 2017; 37:175-186.
-
Tao Y, Chen T, Liu ZY, Wang LQ, Xu WW, Qin LM, Peng GH, Yi-Fei H. Topographic Quantification of the Transcorneal Electrical Stimulation (TES)-Induced Protective Effects on N-Methyl-N-Nitrosourea-Treated Retinas. Invest Ophthalmol Vis Sci. 2016 09 01; 57(11):4614-24.
-
Wang P, Wu J, Ma S, Zhang L, Yao J, Hoadley KA, Wilkerson MD, Perou CM, Guan KL, Ye D, Xiong Y. Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents. Cell Rep. 2015 Dec 22; 13(11):2353-2361.
-
Vo RC, Stafeeva K, Aldave AJ, Stulting RD, Moore Q, Pflugfelder SC, Chungfat NC, Holsclaw DS, Margolis TP, Deng SX. Complications related to a cosmetic eye-whitening procedure. Am J Ophthalmol. 2014 Nov; 158(5):967-73.
-
Sinha MK, Bajaj MS, Pushker N, Ghose S, Chandra M. Efficacy of probing with mitomycin-C in adults with primary acquired nasolacrimal duct obstruction. J Ocul Pharmacol Ther. 2013 Apr; 29(3):353-5.
-
O'Donnell KA, Keng VW, York B, Reineke EL, Seo D, Fan D, Silverstein KA, Schrum CT, Xie WR, Mularoni L, Wheelan SJ, Torbenson MS, O'Malley BW, Largaespada DA, Boeke JD. A Sleeping Beauty mutagenesis screen reveals a tumor suppressor role for Ncoa2/Src-2 in liver cancer. Proc Natl Acad Sci U S A. 2012 May 22; 109(21):E1377-86.
-
Olsen EA, Rook AH, Zic J, Kim Y, Porcu P, Querfeld C, Wood G, Demierre MF, Pittelkow M, Wilson LD, Pinter-Brown L, Advani R, Parker S, Kim EJ, Junkins-Hopkins JM, Foss F, Cacchio P, Duvic M. Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol. 2011 Feb; 64(2):352-404.
-
Ding W, Ferrajoli A. Evidence-based mini-review: the role of alkylating agents in the initial treatment of chronic lymphocytic leukemia patients with the 11q deletion. Hematology Am Soc Hematol Educ Program. 2010; 2010:90-2.